The Emerging Role of Proteomics in Precision Medicine: Applications in Neurodegenerative Diseases and Neurotrauma

  • Rana Alaaeddine
  • Mira Fayad
  • Eliana Nehme
  • Hisham F. BahmadEmail author
  • Firas KobeissyEmail author
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1007)


Inter-individual variability in response to pharmacotherapy has provoked a higher demand to personalize medical decisions. As the field of pharmacogenomics has served to translate personalized medicine from concept to practice, the contribution of the “omics” disciplines to the era of precision medicine seems to be vital in improving therapeutic outcomes. Although we have observed significant advances in the field of genomics towards personalized medicine, the field of proteomics-with all its capabilities- is still in its infancy towards the area of personalized precision medicine. Neurodegenerative diseases and neurotrauma are among the areas where the implementation of neuroproteomics approaches has enabled neuroscientists to broaden their understanding of neural disease mechanisms and characteristics. It has been shown that the influence of epigenetics, genetics and environmental factors were among the recognized factors contributing to the diverse presentation of a single disease as well as its treatment establishing the factor–disease interaction. Thus, management of these variable single disease presentation/outcome necessitated the need for factoring the influence of epigenetics, genetics, epigenetics, and other factors on disease progression to create a custom treatment plan unique to each individual. In fact, neuroproteomics with its high ability to decipher protein alterations along with their post translational modifications (PTMs) can be an ideal tool for personalized medicine goals including: discovery of molecular mechanisms underlying disease pathobiology, development of novel diagnostics, enhancement of pharmacological neurotherapeutic approaches and finally, providing a “proteome identity” for patients with certain disorders and diseases. So far, neuroproteomics approaches have excelled in the areas of biomarker discovery arena where several diagnostic, prognostic and injury markers have been identified with a direct impact on the neurodegenerative diseases and neurotrauma. However, other applications in proteomics such as “individual” proteome sequencing with its signature PTMs, have not been fully investigated as compared to the achievements in the genomics discipline This infers that proteomics research work has promising potential, yet to be discovered, in the precision medicine and comprises a major component of the personalized medicine infrastructure as it allows individual characterization of disease at the protein level. To conclude, the field of proteomics-based personalized medicine is still in its infancy compared to genomics field due to several technical and instrumentation-based obstacles; however, we anticipate to have this initiative leading in the coming future. This chapter will discuss briefly how neuroproteomics can impact personalized medicine in the fields of neurodegenerative disorders particularly in Alzheimer’s disease and brain injury.


Post-translational modifications Neurodegenerative diseases Brain injury Neurotrauma Personalized medicine Alzheimer’s disease proteomics 


  1. 1.
    Collins FS, McKusick VA (2001) Implications of the human genome project for medical science. JAMA 285(5):540–544CrossRefPubMedGoogle Scholar
  2. 2.
    Juengst E, McGowan ML, Fishman JR, Settersten RA Jr (2016) From “Personalized” to “Precision” medicine: the ethical and social implications of rhetorical reform in genomic medicine. Hast Cent Rep 46(5):21–33CrossRefGoogle Scholar
  3. 3.
    Ashley EA (2016) Towards precision medicine. Nat Rev Genet 17(9):507–522CrossRefPubMedGoogle Scholar
  4. 4.
    Schelke MW et al (2016) Nutritional interventions for Alzheimer’s prevention: a clinical precision medicine approach. Ann N Y Acad Sci 1367(1):50–56CrossRefPubMedGoogle Scholar
  5. 5.
    Prince M, Comas-Herrera A, Knapp M, Guerchet M, Karagiannidou M (2016) World Alzheimer report 2016: improving healthcare for people living with dementia: coverage, quality and costs now and in the future. Alzheimer’s Disease International, LondonGoogle Scholar
  6. 6.
    Heron M, Anderson RN (2016) Changes in the leading cause of death: recent patterns in heart disease and cancer mortality. Cancer 400(500000):600000Google Scholar
  7. 7.
    Montine TJ, Montine KS (2015) Precision medicine: clarity for the clinical and biological complexity of Alzheimer’s and Parkinson’s diseases. J Exp Med 212(5):601–605CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Menon DK, Maas AI (2015) Traumatic brain injury in 2014. Progress, failures and new approaches for TBI research. Nat Rev Neurol 11(2):71–72CrossRefPubMedGoogle Scholar
  9. 9.
    Abou-Abbass H et al (2016) Glycosylation and other PTMs alterations in neurodegenerative diseases: current status and future role in neurotrauma. Electrophoresis 37(11):1549–1561CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    DeKosky ST, Blennow K, Ikonomovic MD, Gandy S (2013) Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers. Nat Rev Neurol 9(4):192–200CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Moya-Alvarado G, Gershoni-Emek N, Perlson E, Bronfman FC (2016) Neurodegeneration and Alzheimer’s disease (AD). What can proteomics tell us about the Alzheimer’s brain? Mol Cell Proteomics 15(2):409–425CrossRefPubMedGoogle Scholar
  12. 12.
    Roberts S, Julius M (2016) Precision medicine: now, not when. Healthc Manag Forum 29(4):158–161CrossRefGoogle Scholar
  13. 13.
    Ozdemir V et al (2017) Personalized medicine beyond genomics: alternative futures in big data-proteomics, environtome and the social proteome. J Neural Transm 124(1):25–32CrossRefPubMedGoogle Scholar
  14. 14.
    Colinge J, Rix U, Bennett KL, Superti-Furga G (2012) Systems biology analysis of protein-drug interactions. Proteomics Clin Appl 6(1–2):102–116CrossRefPubMedGoogle Scholar
  15. 15.
    Veenstra TD (2016) Neuroproteomic tools for battling Alzheimer’s disease. Proteomics 16(22):2847–2853CrossRefPubMedGoogle Scholar
  16. 16.
    Henderson M et al (2016) Neuroproteomic study of nitrated proteins in moderate traumatic brain injured rats treated with gamma glutamyl cysteine ethyl ester administration post injury: Insight into the role of glutathione elevation in nitrosative stress. PROTEOMICS – Clin Appl 10(12):1218–1224CrossRefPubMedGoogle Scholar
  17. 17.
    Kobeissy FH et al (2016) Neuroproteomics and systems biology approach to identify temporal biomarker changes post experimental traumatic brain injury in rats. Front Neurol 7Google Scholar
  18. 18.
    Xu B et al (2016) Protein profile changes in the frontotemporal lobes in human severe traumatic brain injury. Brain Res 1642:344–352CrossRefPubMedGoogle Scholar
  19. 19.
    Thelin EP et al. (2016) Protein profiling in serum after traumatic brain injury in rats reveals potential injury markers. Behav Brain Res. Google Scholar
  20. 20.
    Crawford F et al (2012) Identification of plasma biomarkers of TBI outcome using proteomic approaches in an APOE mouse model. J Neurotrauma 29(2):246–260CrossRefPubMedGoogle Scholar
  21. 21.
    Kovacech B, Zilka N, Novak M (2009) New age of neuroproteomics in Alzheimer’s disease research. Cell Mol Neurobiol 29(6–7):799–805CrossRefPubMedGoogle Scholar
  22. 22.
    Jaber Z et al (2016) Role of systems biology in brain injury biomarker discovery: neuroproteomics application. Methods Mol Biol 1462:157–174CrossRefPubMedGoogle Scholar
  23. 23.
    Brinkmalm A et al (2015) Explorative and targeted neuroproteomics in Alzheimer’s disease. Biochim Biophys Acta 1854(7):769–778CrossRefPubMedGoogle Scholar
  24. 24.
    Gozal YM et al (2009) Proteomics analysis reveals novel components in the detergent-insoluble subproteome in Alzheimer’s disease. J Proteome Res 8(11):5069–5079CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Musunuri S et al (2014) Quantification of the brain proteome in Alzheimer’s disease using multiplexed mass spectrometry. J Proteome Res 13(4):2056–2068CrossRefPubMedGoogle Scholar
  26. 26.
    Federico VR, Federica F (2016) Functional proteomics as marker for neurological and psychiatric disorders: the first application to dementia for an immediate future. J Neurol Neurosci 7:S2CrossRefGoogle Scholar
  27. 27.
    Li KW, Klemmer P, Smit AB (2010) Interaction proteomics of synapse protein complexes. Anal Bioanal Chem 397(8):3195–3202CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Ansari MA, Roberts KN, Scheff SW (2008) A time course of contusion-induced oxidative stress and synaptic proteins in cortex in a rat model of TBI. J Neurotrauma 25(5):513–526CrossRefPubMedGoogle Scholar
  29. 29.
    Yu C et al (2015) A systems biology strategy to identify molecular mechanisms of action and protein indicators of traumatic brain injury. J Neurosci Res 93(2):199–214CrossRefPubMedGoogle Scholar
  30. 30.
    Chang RY, Nouwens AS, Dodd PR, Etheridge N (2013) The synaptic proteome in Alzheimer’s disease. Alzheimer’s Dement J Alzheimer’s Assoc 9(5):499–511CrossRefGoogle Scholar
  31. 31.
    Zali H, Tavirani MR, Jalilian FA, Khodarahmi R (2013) Proteins expression clustering of Alzheimer disease in rat hippocampus proteome. J Paramedical Sci 4(3):111–118Google Scholar
  32. 32.
    Butterfield DA, Reed TT (2016) Lipid peroxidation and tyrosine nitration in traumatic brain injury: insights into secondary injury from redox proteomics. Proteomics Clin Appl 10(12):1191–1204CrossRefPubMedGoogle Scholar
  33. 33.
    Lazarus RC, Buonora JE, Jacobowitz DM, Mueller GP (2015) Protein carbonylation after traumatic brain injury: cell specificity, regional susceptibility, and gender differences. Free Radic Biol Med 78:89–100CrossRefPubMedGoogle Scholar
  34. 34.
    Seneviratne U et al (2016) S-nitrosation of proteins relevant to Alzheimer’s disease during early stages of neurodegeneration. Proc Natl Acad Sci U S A 113(15):4152–4157CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Bayes A, Grant SG (2009) Neuroproteomics: understanding the molecular organization and complexity of the brain. Nat Rev Neurosci 10(9):635–646CrossRefPubMedGoogle Scholar
  36. 36.
    D’Alessandro A, Rinalducci S, Zolla L (2011) Redox proteomics and drug development. J Proteome 74(12):2575–2595CrossRefGoogle Scholar
  37. 37.
    Kitamura Y et al (2017) Plasma protein profiling for potential biomarkers in the early diagnosis of Alzheimer’s disease. Neurol Res 39(3):231–238CrossRefPubMedGoogle Scholar
  38. 38.
    Lovestone S et al (2007) Proteomics of Alzheimer’s disease: understanding mechanisms and seeking biomarkers. Expert Rev Proteomics 4(2):227–238CrossRefPubMedGoogle Scholar
  39. 39.
    Liao L et al (2004) Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. J Biol Chem 279(35):37061–37068CrossRefPubMedGoogle Scholar
  40. 40.
    Thomas SN et al (2012) Dual modification of Alzheimer’s disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach. Acta Neuropathol 123(1):105–117CrossRefPubMedGoogle Scholar
  41. 41.
    Troncone L et al (2016) Abeta amyloid pathology affects the hearts of patients with Alzheimer’s disease: mind the heart. J Am Coll Cardiol 68(22):2395–2407CrossRefPubMedGoogle Scholar
  42. 42.
    Gerson J et al (2016) Tau oligomers derived from traumatic brain injury cause cognitive impairment and accelerate onset of pathology in Htau mice. J Neurotrauma 33(22):2034–2043CrossRefPubMedGoogle Scholar
  43. 43.
    Johnson VE, Stewart W, Smith DH (2010) Traumatic brain injury and amyloid-beta pathology: a link to Alzheimer’s disease? Nat Rev Neurosci 11(5):361–370PubMedPubMedCentralGoogle Scholar
  44. 44.
    Roberts GW, Gentleman SM, Lynch A, Graham DI (1991) beta A4 amyloid protein deposition in brain after head trauma. Lancet 338(8780):1422–1423CrossRefPubMedGoogle Scholar
  45. 45.
    Roberts GW et al (1994) Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 57(4):419–425CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Raby CA et al (1998) Traumatic brain injury increases beta-amyloid peptide 1-42 in cerebrospinal fluid. J Neurochem 71(6):2505–2509CrossRefPubMedGoogle Scholar
  47. 47.
    Butterfield DA, Dalle-Donne I (2012) Redox proteomics. Antioxid Redox Signal 17(11):1487–1489CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Sheehan D, McDonagh B, Barcena JA (2010) Redox proteomics. Expert Rev Proteomics 7(1):1–4CrossRefPubMedGoogle Scholar
  49. 49.
    McDonagh B, Sheehan D (2008) Effects of oxidative stress on protein thiols and disulphides in Mytilus edulis revealed by proteomics: actin and protein disulphide isomerase are redox targets. Mar Environ Res 66(1):193–195CrossRefPubMedGoogle Scholar
  50. 50.
    Butterfield DA, Sultana R (2008) Redox proteomics: understanding oxidative stress in the progression of age-related neurodegenerative disorders. Expert Rev Proteomics 5(2):157–160CrossRefPubMedGoogle Scholar
  51. 51.
    Keller JN et al (2005) Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64(7):1152–1156CrossRefPubMedGoogle Scholar
  52. 52.
    Beretta G, Facino RM (2010) Recent advances in the assessment of the antioxidant capacity of pharmaceutical drugs: from in vitro to in vivo evidence. Anal Bioanal Chem 398(1):67–75CrossRefPubMedGoogle Scholar
  53. 53.
    Di Domenico F et al (2016) Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients. Free Radic Biol Med 91:1–9CrossRefPubMedGoogle Scholar
  54. 54.
    Keeney JT et al (2013) Apolipoprotein A-I: insights from redox proteomics for its role in neurodegeneration. Proteomics Clin Appl 7(1–2):109–122CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Shoemaker LD, Achrol AS, Sethu P, Steinberg GK, Chang SD (2012) Clinical neuroproteomics and biomarkers: from basic research to clinical decision making. Neurosurgery 70(3):518–525CrossRefPubMedGoogle Scholar
  56. 56.
    Jauch EC et al (2006) Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator stroke study. Stroke 37(10):2508–2513CrossRefPubMedGoogle Scholar
  57. 57.
    Duarte TT, Spencer CT (2016) Personalized proteomics: the future of precision medicine. Proteomes 4(4)Google Scholar
  58. 58.
    Scherl A (2015) Clinical protein mass spectrometry. Methods 81:3–14CrossRefPubMedGoogle Scholar
  59. 59.
    Lehmann S, et al. (2016) Clinical mass spectrometry proteomics (cMSP) for medical laboratory: what does the future hold? Clin Chim Acta; Int J Clin ChemGoogle Scholar
  60. 60.
    Guest FL, Guest PC, Martins-de-Souza D (2016) The emergence of point-of-care blood-based biomarker testing for psychiatric disorders: enabling personalized medicine. Biomark Med 10(4):431–443CrossRefPubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2017

Authors and Affiliations

  1. 1.Department of Pharmacology and Therapeutics, Faculty of MedicineAmerican University of BeirutBeirutLebanon
  2. 2.Biomedical Engineering Program, Faculty of Engineering and Architecture and Faculty of MedicineAmerican University of BeirutBeirutLebanon
  3. 3.Department of Biochemistry and Molecular Genetics, Faculty of MedicineAmerican University of BeirutBeirutLebanon
  4. 4.Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of MedicineAmerican University of BeirutBeirutLebanon

Personalised recommendations